ORGANIZATION

Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023

July 25, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The total number of drug reps in Japan dwindled by nearly 3,000, or 6.0%, in FY2023, recording the 10th straight year of decreases, according to the MR Education & Accreditation Center of Japan’s annual white paper published on July 25.…

To read the full story

Japan Logs 11th Straight Year of Decline in Drug Reps, Voluntary Buyouts Likely a Major Factor
July 16, 2025
Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023

ORGANIZATION

Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
Raise Foreign Price Adjustment Cap for Listed Products in German Cases: FPMAJ
June 15, 2026
FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026
Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag

By Hayate Horiguchi

Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…